Edwards Lifesciences Ag v. Corevalve, Inc.
Decision Date | 04 February 2013 |
Docket Number | 2011–1257.,Nos. 2011–1215,s. 2011–1215 |
Citation | 699 F.3d 1305 |
Parties | EDWARDS LIFESCIENCES AG and Edwards Lifesciences LLC, Plaintiffs–Cross Appellants, v. COREVALVE, INC. and Medtronic CoreValve, LLC, Defendants–Appellants. |
Court | U.S. Court of Appeals — Federal Circuit |
OPINION TEXT STARTS HERE
John E. Nathan, Paul, Weiss, Rifkind, Wharton & Garrison, LLP, of New York, NY, argued for plaintiffs-cross appellants. With him on the brief were Catherine Nyarady, Kripa Raman, Brian P. Egan and Robert A. Weinstock. Of counsel on the brief was Jack B. Blumenfeld, of Wilmington, DE.
Jeffrey W. Sarles, Mayer Brown LLP, of Chicago, IL, argued for defendants-appellants. With him on the brief were James R. Ferguson, Melissa A. Anyetei and Brent A. Batzer. Of counsel on the brief were Donald M. Falk and Rita K. Lomio, of Palo Alto, CA.
Before RADER, Chief Judge, NEWMAN and PROST, Circuit Judges.
Opinion for the court filed by Circuit Judge NEWMAN.
Edwards Lifesciences AG and Edwards Lifesciences LLC (collectively “Edwards”) sued defendants CoreValve, Inc. and its successor in interest Medtronic CoreValve, LLC (collectively “CoreValve”) for infringement of United States Patent No. 5,411,552 (“the '552 patent”) issued May 2, 1995, entitled “Valve Prosthesis for Implantation in the Body and a Catheter for Implanting Such Valve Prosthesis.” Two other patents, initially in suit, are not at issue. The inventors are Dr. Henning R. Andersen, an interventional cardiologist at Aarhus Medical School in Denmark, his surgical colleague Dr. John M. Hasenkam, and then medical student Lars L. Knudsen.
The invention is a prosthetic device called a “transcatheter heart valve.” The valve is mounted on a stent and implanted in the heart by catheter, thereby avoiding open heart surgery and its associated risks. Suit for infringement was brought in the United States District Court for the District of Delaware, trial was to a jury, and the verdict was that the '552 patent is valid, that CoreValve's Generation 3 ReValving System infringed patent claim 1, and that the infringement was willful. The jury awarded damages of $72,645,555 in lost profits and $1,284,861 as a reasonable royalty.1
The district court entered judgment on the verdict, but declined to enhance damages for the willful infringement. The court also declined to issue an injunction against future infringement, apparently on CoreValve's representation that, if enjoined, it would move its manufacturing operations to Mexico. The court also denied Edwards' request to modify the litigation-agreed protective order and to permit Edwards' patent counsel and technical expert to participate in the ongoing reexamination proceedings of the patent in suit and related patents. Each party appeals the rulings adverse to it.
We affirm the district court's rulings, except that we remand for reconsideration of the court's denial of an injunction in view of the representation of changed circumstances, and for reconsideration of the court's ruling on the protective order as applied to patents not in suit, to the extent that this issue has not become moot.
Validity of the '552 patent
The '552 patent is directed to a collapsible stent that carries a valve for insertion into the heart by balloon catheter. Figure 1 of the '552 patent shows the collapsible stent with projecting apices at 4. Figure 2 includes the elastically collapsible valve 6 held to the apices at commissural points 5:
Image 1 (2.33" X 2.37") Available for Offline Print
To implant the valve, the stent and valve are compressed into a balloon catheter, and moved through a blood vessel for release at the implantation site, where the balloon expands the stent and wedges it into the desired location for the valve. The patent illustrates various placements of the valve in the heart. Figure 8 describes “a position between the coronary arteries 20 and the left ventricle of the heart 21:”
The only ground on which CoreValve challenged validity of the patent was for lack of enablement based on the undisputed fact that at the time the '552 patentapplication was filed the stent/valve prosthesis had been implanted only in pigs. CoreValve also pointed out that the various experimental implants in pigs were not always successful, and that design changes were made after the patent application was filed.
Edwards agrees that more developmental work was required at the time of filing. Co-inventor Knudsen wrote, in a contemporaneous report, that “questions such as size reduction, material and design optimization, and stent valve sterilization, remain unsolved,” and that “much more work had to be done before anybody ever even contemplated using this for a human.” Edwards' expert witness Dr. Buller testified that at the time the patent application was filed, it was “a device to perform testing on” and “not a device to move in and treat patients.” The jury was instructed on the issue of enablement as follows:
The Patent Laws require that the patent be sufficiently detailed to enable those skilled in the art to practice the invention. The purpose of this requirement is to ensure that the public, in exchange for the patent rights given to the inventor, obtains from the inventor a full disclosure of how to make and use the invention.
If the inventors failed to provide an enabling disclosure, the patent is invalid. However, because descriptions in patents are addressed to those skilled in the art to which the invention pertains, an applicant for a patent need not expressly set forth in his specification subject matter which is commonly understood by persons skilled in the art.
The enablement defense does not require an intent to withhold; all that is required is a failure to teach how to practice the full scope of the claimed invention. In other words, if a person of ordinary skill in the art could not make and use the invention disclosed in the patent without undue experimentation, the patent is invalid. However, some routine amount of experimentation to make and use the invention is allowable.
The patent need not contain a working example if the invention is otherwise disclosed in such a manner that one skilled in the art to which the invention pertains will be able to practice it without an undue amount of experimentation.
Final Jury Instructions at 25 (April 1, 2010).
This instruction correctly states the law. Precedent establishes that “[t]he enablement requirement is met if the description enables any mode of making and using the invention.” Johns Hopkins Univ. v. CellPro, Inc., 152 F.3d 1342, 1361 (Fed.Cir.1998) (quoting Engel Indus., Inc. v. Lockformer Co., 946 F.2d 1528, 1533 (Fed.Cir.1991)). See also Transocean Offshore Deepwater Drilling, Inc. v. Maersk Contractors USA, Inc., 617 F.3d 1296, 1307 (Fed.Cir.2010) (); Durel Corp. v. Osram Sylvania Inc., 256 F.3d 1298, 1307 (Fed.Cir.2001) (). Continuing development is often contemplated and necessary, while early filing is often essential.
CoreValve argues that in no event does testing in pigs enable use in humans. However, it has long been recognized that when experimentation on human subjects is inappropriate, as in the testing and development of drugs and medical devices, the enablement requirement may be met by animal tests or in vitro data. SeeMPEP § 2164.02 (). This general rule has been elaborated in various situations, e.g., In re Brana, 51 F.3d 1560, 1566 (Fed.Cir.1995) (); Scott v. Finney, 34 F.3d 1058, 1063 (Fed.Cir.1994) ( ) .
Useful criteria for determination of enablement for purposes of section 112 are summarized in In re Wands, 858 F.2d 731 (Fed.Cir.1988). Factors to be considered in determining whether the subject matter requires undue experimentation include “(1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claims.” Id. at 737.
There was evidence that the stent/valve prosthetic device was successfully implanted in pigs, in accordance with the procedure described in the '552 specification. It was explained that pigs were a standard experimental animal for heart valve research. Witnesses for both sides discussed the vascular anatomies of pigs and the established use of porcine valves in humans. Witnesses discussed the nature of the ongoing experimentation, in light of the district court's instruction on the enablement requirement. We agree with the district court that substantial evidence supported the jury verdict that invalidity on the ground of non-enablement had not been proved...
To continue reading
Request your trial-
In re Biogen 755 Patent Litig.
...determinations and believe the witness it considers more trustworthy." (citation omitted) ); Edwards Lifesciences AG v. CoreValve, Inc. , 699 F.3d 1305, 1313 (Fed. Cir. 2012) (noting that when "testimony at trial [is] in direct conflict," the court deciding a JMOL motion "may not weigh the ......
-
W. Plastics, Inc. v. Dubose Strapping, Inc.
...in the art, the predictability or unpredictability of the art, and the breadth of the claims. See, e.g., Edwards Lifescis. AG v. CoreValve, Inc., 699 F.3d 1305, 1310 (Fed. Cir. 2012).DuBose argues that the '304 Patent fails to teach a person of ordinary skill how to make a puncture, tear, a......
-
Power Integrations, Inc. v. Fairchild Semiconductor Int'l, Inc.
...Lifesciences AG v. CoreValve, Inc., No. 08–91–GMS, 2011 WL 446203, at *16 (D.Del. Feb. 7, 2011), aff'd in part, remanded in part,699 F.3d 1305 (Fed.Cir.2012) (“The court will grant ... an accounting of the number of [infringing] devices made, used, sold ... through the date of the order acc......
-
Ameritox, Ltd. v. Millennium Health, LLC
...when ... one of ordinarily skill in the art could not practice their full scope without undue experimentation”); see also Edwards Lifesciences AG v. CoreValve, Inc., 699 F.3d 1305, 1309 (Fed.Cir.2012) (“The enablement defense does not require an intent to withhold; all that is required is a......
-
Chapter §20.02 Injunctions
...the tenor of other Federal Circuit decisions was not as clear on this point. For example, in Edwards Lifesciences AG v. CoreValve, Inc., 699 F.3d 1305 (Fed. Cir. 2012), the majority vacated a district court's denial of a permanent injunction and stated that "[a]bsent adverse equitable consi......
-
Chapter §20.05 Enhanced Damages and Willful Infringement
...finding of willfulness does not require an award of enhanced damages; it merely permits it"); Edwards Lifesciences AG v. CoreValve, Inc., 699 F.3d 1305, 1314 (Fed. Cir. 2012) (discerning no abuse of discretion in district court's decision not to enhance damages (or award attorney fees) desp......
-
INJURY, INEQUALITY, AND REMEDIES: DEVELOPMENTS IN INJUNCTIVE RELIEF AND DAMAGES IN INTELLECTUAL PROPERTY CASES.
...case-by-case assessment of the traditional equitable factors governing injunctions). See also Edwards Lifesciences AG v. CoreValve, Inc., 699 F. 3d 1305, 1314-15 (Fed. Cir. 2012) (vacating denial of injunction to practicing patentee after citing this typical scenario from Medtronic); Presid......
-
CHAPTER § 3.03 Litigation Practices and Liability
...Id. (quotations and citations omitted).[351] Id. (quotations and citations omitted).[352] Edwards Lifesciences AG v. CoreValve, Inc., 699 F.3d 1305, 1309 (Fed. Cir. 2012).[353] See In re '318 Patent Infringement Litig., 583 F.3d 1317 (Fed. Cir. 2009).[354] Ariad, 598 F.3d at 1351.[355] Id.[......